about
Speciation of insulin-mimetic VO(IV)-containing drugs in blood serum.Antitumoral effect of vanadium compounds in malignant melanoma cell lines.Doubly end-on azido bridged mixed-valence cobalt trinuclear complex: Spectral study, VTM, inhibitory effect and antimycobacterial activity on human carcinoma and tuberculosis cells.Structural and redox requirements for the action of anti-diabetic vanadium compounds.Characterization and biotransformation in the plasma and red blood cells of V(IV)O(2+) complexes formed by ceftriaxone.Synthesis of Nitric Oxide Donors Derived from Piloty's Acid and Study of Their Effects on Dopamine Secretion from PC12 CellsThe equilibrium between the octahedral and square pyramidal form and the influence of an axial ligand on the molecular properties of V(IV)O complexes: a spectroscopic and DFT study.A quantitative study of the biotransformation of insulin-enhancing VO(2+) compounds.New developments in the comprehension of the biotransformation and transport of insulin-enhancing vanadium compounds in the blood serum.Bis- and tris(pyridyl)amine-oxidovanadium complexes: characteristics and insulin-mimetic potential.Copper(II) complexes of rat amylin fragments.Reversible switching of the electronic ground state in a pentacoordinated Cu(II) complex.Complex formation of vanadium(IV) with 1,3,5-triamino-1,3,5-trideoxy-cis-inositol and related ligands.Vanadium(IV,V) complexes of D-saccharic and mucic acids in aqueous solution.Formation in aqueous solution of a non-oxido V(IV) complex with VN6 coordination. Potentiometric, ESI-MS, spectroscopic and computational characterization.On the transport of vanadium in blood serum.Assessing the dependence of (51)V A(z) value on the aromatic ring orientation of V(IV)O(2+) pyridine complexes.Aminoacid-derivatised picolinato-oxidovanadium(IV) complexes: characterisation, speciation and ex vivo insulin-mimetic potential.Elucidation of Binding Site and Chiral Specificity of Oxidovanadium Drugs with Lysozyme through Theoretical Calculations.Monomeric and Dimeric Oxidomolybdenum(V and VI) Complexes, Cytotoxicity, and DNA Interaction Studies: Molybdenum Assisted C═N Bond Cleavage of Salophen Ligands.Speciation in human blood of Metvan, a vanadium based potential anti-tumor drug.Speciation of potential anti-diabetic vanadium complexes in real serum samples.Potentiometric, spectroscopic, electrochemical and DFT characterization of oxovanadium(IV) complexes formed by citrate and tartrates in aqueous solution at high ligand to metal molar ratios: the effects of the trigonal bipyramidal distortion in bis-Nonoxido V(IV) Complexes: Prediction of the EPR Spectrum and Electronic Structure of Simple Coordination Compounds and Amavadin.Synthesis of two new linear trinuclear Cu(II) complexes: mechanism of magnetic coupling through hybrid B3LYP functional and CShM studies.Behavior of the potential antitumor V(IV)O complexes formed by flavonoid ligands. 3. Antioxidant properties and radical production capability.Biorelevant reactions of the potential anti-tumor agent vanadocene dichloride.Behavior of the potential antitumor V(IV)O complexes formed by flavonoid ligands. 2. Characterization of sulfonate derivatives of quercetin and morin, interaction with the bioligands of the plasma and preliminary biotransformation studies.Speciation of the Potential Antitumor Agent Vanadocene Dichloride in the Blood Plasma and Model Systems.Determination of the hyperfine coupling constant and zero-field splitting in the ESR spectrum of Mn(2+) in calcite.Chelating ability and biological activity of hesperetin Schiff base.Switching and redox isomerism in first-row transition metal complexes containing redox active Schiff base ligands.Behavior of the potential antitumor V(IV)O complexes formed by flavonoid ligands. 1. Coordination modes and geometry in solution and at the physiological pH.Synthesis and characterization of V(IV)O complexes of picolinate and pyrazine derivatives. Behavior in the solid state and aqueous solution and biotransformation in the presence of blood plasma proteins.Interaction of antidiabetic vanadium compounds with hemoglobin and red blood cells and their distribution between plasma and erythrocytes.Interaction of insulin-enhancing vanadium compounds with human serum holo-transferrin.Physicochemical, antioxidant, DNA cleaving properties and antimicrobial activity of fisetin-copper chelates.Prediction of the interaction of metallic moieties with proteins: An update for protein-ligand docking techniques.VIVO complexes with antibacterial quinolone ligands and their interaction with serum proteins.Binding of V(IV)O²⁺ to the Fe binding sites of human serum transferrin. A theoretical study.
P50
Q33961264-4F555971-D89B-468C-BBBC-DCCD820C40D3Q38701856-97789A87-60B2-47C6-8F65-6D48BC6684BAQ38880219-0EB1AB69-93B2-4735-8459-A7CC0C0251F3Q39011814-A7CF7D4A-712F-4B88-9FF3-21DA0E5C8FC5Q41560185-9EDF132E-1AC7-452F-87DB-6EC16F2E7BD4Q41877565-5ED38A86-0609-4902-9351-2CCFCB92B6B7Q43038476-C9AC5936-5A42-4F7E-9637-285E26691911Q43117921-32A601B0-1C51-468F-B637-43BA57F9C689Q43233689-5E7CF07A-FEB0-4D67-9057-785EC05FBAB3Q43273285-4FB7CF82-A175-45A4-9E02-D7853E10674BQ44409592-99CCE46C-4BC2-4BFC-94B1-928B77985175Q44720934-06103B42-766E-4DCC-85FB-3182510AD8DAQ44887664-D0E653CD-E819-403A-99A9-A465CBAFC3BCQ45069938-B8814BE1-6ACA-4323-ABF4-BFBF76D8D5DAQ45423532-B486E71C-9D47-488A-9011-E23721AA79D4Q45974824-14821438-A835-430D-8A9B-4D74A1DCB607Q46007554-4AA00851-4B97-416A-8CC3-6361B066829AQ46176264-B05BD80A-F3A5-48AB-A4AD-47227F7BE828Q46292820-02A058E2-92C7-454F-BAC9-E6800669D365Q46313875-A86BCBBA-46FF-47BC-9815-341785BBC7B2Q46346192-AD37B1CC-9D04-4533-BED6-22A3F61C4790Q46366918-209D0ECB-9B5C-4B38-85CF-9A908F0E8336Q46394659-EF3CC183-166E-40F0-A207-8B0CCDDCE0AEQ46518261-6A173057-496B-4EA2-8C9E-47DE6A44C7A2Q46524094-262EFE16-B531-4A2B-B2CA-AD5C5DA9BA77Q46547649-2B84F37F-EE34-46DB-BE33-045C3D913996Q46556968-45F7613C-5E96-43C4-94CF-3FB444043B9EQ46683303-5ADBC1A3-5875-4F3E-9EDF-D5342FBE6CD1Q46683447-42B81351-83FC-4186-9320-B02E57A6B849Q46784567-92243AD4-47CF-47CE-8AEB-CC552CF14B2FQ46801292-B8920B52-4329-4019-8954-9499ACFAF62EQ46837161-E42A3517-10E1-4F1E-AE16-228269FF2962Q46851740-96D7B3D1-1C84-40FF-B3A4-73796A2E31C3Q46867884-25E2AB70-64C8-4526-92C9-942534F1FC92Q46944893-C9B0D886-D91F-4F12-A704-9F7CEDB2BF18Q46987554-26E9C713-6EA4-4757-99C8-C0C516AC49C0Q47243860-C8B4AB36-0F55-4C2B-B80E-E42E9BBC081CQ47596686-B3E8B19D-87F0-448F-8258-7B799CF5DE80Q47720108-2AC93C6E-32DD-4C3E-8683-14BDA1F18559Q47744197-EF2BFB17-EB55-413E-ACED-6256FB1506F5
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Eugenio Garribba
@ast
Eugenio Garribba
@en
Eugenio Garribba
@es
Eugenio Garribba
@nl
Eugenio Garribba
@sl
type
label
Eugenio Garribba
@ast
Eugenio Garribba
@en
Eugenio Garribba
@es
Eugenio Garribba
@nl
Eugenio Garribba
@sl
prefLabel
Eugenio Garribba
@ast
Eugenio Garribba
@en
Eugenio Garribba
@es
Eugenio Garribba
@nl
Eugenio Garribba
@sl
P106
P21
P31
P496
0000-0002-7229-5966